Navigation Links
CMDBioscience Appoints Tomi Sawyer to Scientific Advisory Board; Entrepreneurial Drug Hunter and Distinguished Scholar Named as Founding Chair
Date:11/22/2013

New Haven, Conn. (PRWEB) November 22, 2013

CMDBioscience Inc., a pioneering innovator in peptide drug design and computational modeling, today announced the appointment of Tomi Sawyer, Ph.D., as the founding chair of its Scientific Advisory Board. Dr. Sawyer joins Victor Hruby, Ph.D., Bernhardt Trout, Ph.D., Benjamin Wolozin, Ph.D., and Yaoqi Zhou, Ph.D. as founding members of the Scientific Advisory Board.

Dr. Sawyer received his doctorate from the University of Arizona and is currently an adjunct professor at the University of Massachusetts (Department of Chemistry and Department of Biochemistry and Molecular Biology), the University of Massachusetts Medical School (Department of Cancer Biology), and Northeastern University (Center of Drug Discovery).

He was the founding chief scientific officer and senior vice president of drug discovery and innovative technologies at Aileron Therapeutics. Tomi has more than 30 years of pharmaceutical industry and biotech experience with multidisciplinary expertise in drug discovery and translational medicine with a focus on advancing peptides, peptidomimetics, and proteomimetics, natural products and small-molecules into the clinic. He is a former president of the American Peptide Society and founding editor-in-chief of Chemical Biology and Drug Design. Dr. Sawyer is credited with more than 320 publications and patents, and has presented nearly 200 keynote, plenary and invited lectures.

“We are delighted to have Tomi join the CMDBioscience team as the chair of our Scientific Advisory Board,” said Joseph Audie, chief executive officer of CMDBioscience. “Tomi has established a world-renowned reputation as both a scholar and leader in peptide drug discovery and brings an unrivaled wealth of expertise in peptide drug discovery and translational medicine to our Scientific Advisory Board.”

Dr. Sawyer’s responsibilities will include helping CMDBioscience to expand its cutting-edge and proprietary computational technology platform (CMDInventus) and forging strategic relationships with leading pharmaceutical and biotechnology companies.

“It’s an exciting time at CMDBioscience as we strive to be a formidable partner in peptide drug discovery,” said Dr. Audie. “The appointment of Tomi to the board further underscores our commitment to achieving the vision of transforming peptide drug discovery.”

“I’m very pleased to support the scientific and business vision of the CMDBioscience leadership team and board of directors,” said Dr. Sawyer. “The CMDBioscience drug design and computational modeling platform helps to accelerate peptide drug discovery and works with other key enabling technologies to advance future peptide therapeutics.”

About CMDBioscience
CMDBioscience is a computational biotechnology company that specializes in the development and application of proprietary computational methods to enable peptide drug discovery.

CMDBioscience has developed and enjoys exclusive access to CMDInventus, our proprietary computational peptide discovery platform. Using CMDInventus, CMDBioscience can help partner organizations efficiently identify novel peptide hits, understand the structural basis of target-peptide interactions, facilitate peptide hit-to-lead optimization and help solve a myriad of other peptide discovery problems.

CMDBioscience seeks to accelerate rational peptide discovery and increase value through collaborative peptide discovery partnerships. By working with CMDBioscience, our partners will gain privileged access to CMDInventus and our expertise, ultimately producing superior peptide-based discovery outcomes and increased value.

For more information on CMDBioscience, please visit http://www.cmdbioscience.com.

Read the full story at http://www.prweb.com/releases/2013/11/prweb11362570.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Boston Biomedical Appoints Patricia S. Andrews as Chief Commercial Officer
2. Regado Biosciences, Inc. Appoints World-Renowned Leader in Cardiovascular Research and Former Global Head of Cardiovascular Diseases for Merck & Co., to Board of Directors
3. Convoy Therapeutics Appoints Clinical Advisory Board
4. Egenix, Inc. Appoints Matthew Fury, M.D., Ph.D. to its Scientific Advisory Committee
5. Metamark Appoints Cornelius J. Merlini Chief Commercial Officer
6. ACTUS Appoints New Members to Its Management Team
7. Immune Design Appoints Stephen R. Brady Chief Business Officer
8. DiaVacs, Inc. Appoints Orville Kolterman, M.D. As Chief Medical Officer
9. Sanomedics International Holdings, Inc. appoints new Chairman of the Board and installs new Director of Business Development.
10. Solulink Appoints Life Science Industry Veteran Jack Ball as Chief Executive Officer
11. Cold Spring Harbor Laboratory Appoints Teri F. Willey to Accelerate Commercialization Efforts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 1, 2016   SurePure, Inc. (OTCQB: SURP) ... the Company has concluded an agreement with Tamarack Biotics ... 90-day period to acquire units of the Company,s patented ... 3.7 million.  Concurrently with the option, ... which Tamarack will seek regulatory approvals in ...
(Date:11/30/2016)... 30, 2016 The global Pyrogen ... hold a dominant share in the overall market. The ... Inc., and Merck KGaA, held a lion,s share of ... Research observes that these companies are expected to retain ... that are do not require rabbit pyrogen testing along ...
(Date:11/30/2016)... 30, 2016  Tempus, a technology company focused ... Penn,s Abramson Cancer Center have partnered to better ... to immunotherapy treatment based on next generation genomic ... of a research collaboration, Tempus will provide sequencing ... patient data to Penn. Utilizing next-generation sequencing, machine ...
(Date:11/30/2016)... IN (PRWEB) , ... November 30, 2016 , ... SSCI, ... experts to discuss the implications of the latest FDA guidance on pharmaceutical cocrystals ... 8, 2016 in Cambridge, MA. , The event follows the successful November ...
Breaking Biology Technology:
(Date:11/30/2016)... and WARSAW, Poland , Nov. 30, 2016 ... is one of the most crucial aspects of recovery so we need to do ... serious health risks, including heart problems, high blood pressure, stroke, diabetes, and even cancer. ... friends sleep and find a Christmas present that could help them to manage their ... ...
(Date:11/28/2016)... "The biometric system market projected to ... system market is in the growth stage and is ... biometric system market is expected to be valued at ... 16.79% between 2016 and 2022. Government initiative in adoption ... rising use of biometric technology in financial institutes and ...
(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, a ... for public safety, investigation, corrections and monitoring, announced today ... competitor, ICSolutions, to have an independent technology judge determine ... most modern high tech/sophisticated telephone calling platform, and the ... that they do most of what we do – ...
Breaking Biology News(10 mins):